Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78520 | 0.85 | DGAT1 (0.46) | DGAT1GAAUSP2SMN1; SMN2 | |
| Hydrazine SCHEMBL10794464 | 0.79 | DGAT1 (0.42) | DGAT1GAAUSP2SMN1; SMN2 | |
| SCHEMBL3844213 | 0.77 | DGAT1 (0.40) | DGAT1GAAUSP2SMN1; SMN2 | |
| SCHEMBL9395613 | 0.77 | DGAT1 (0.40) | DGAT1GAAUSP2SMN1; SMN2 | |
| SCHEMBL1088879 | 0.77 | DGAT1 (0.40) | DGAT1GAAUSP2SMN1; SMN2 | |
| SCHEMBL29399642 | 0.76 | — | — | |
| SCHEMBL2404498 | 0.74 | — | — | |
| SCHEMBL10883850 | 0.74 | DGAT1 (0.39) | DGAT1USP2SMN1; SMN2 | |
| SCHEMBL4288100 | 0.74 | DGAT1 (0.50) | DGAT1GAA | |
| SCHEMBL13891390 | 0.74 | DGAT1 (0.39) | DGAT1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-0850928-B1 | Novel peroxyoxalates derived from hydroxy-hydroperoxides | ATOFINA CHEM INC (US) | 2001-10-31 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| EP-0850929-B1 | Novel bis(mono- and diperoxy-oxalates) derived from dihydroperoxides and alkyl and alkylperoxy halooxalates | ATOFINA CHEM INC (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5981787-A | INITIATORS FOR POLYMERIZING ETHYLENICALLY UNSATURATED MONOMERS AND FOR CURING OF UNSATURATED POLYESTER RESINS | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1999-11-09 | — | — | US | disclosed |
| US-5837782-A | POLYMERIZATION CATALYST | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0850929-A1 | Novel bis(mono- and diperoxy-oxalates) derived from dihydroperoxides and alkyl and alkylperoxy halooxalates | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850928-A1 | Novel peroxyoxalates derived from hydroxy-hydroperoxides | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1998-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | DGAT1 1159/4885GAA 2589/4885USP2 4522/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | DGAT1 1159/4885GAA 2589/4885USP2 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.